In a multicenter retrospective study, baseline obesity (BMI ≥ 30 kg/m2) was significantly associated with improved clinical outcomes in patients with metastatic NSCLC with PD-L1 ≥ 50% receiving first-line pembrolizumab. Here, CD274 is linked to obesity disorder.